Syngene International Limited , a leading contract research and manufacturing services company, has reported a strong start to the fiscal year 2026, with revenue from operations growing by 11% year-on-year to Rs. 875.00 crore in the first quarter ended June 30, 2025.

Financial Highlights

• Revenue from operations increased to Rs. 875.00 crore, up from Rs. 790.00 crore in Q1 FY25
• Reported EBITDA rose by 19% year-on-year to Rs. 224.00 crore
• EBITDA margin improved to 25%, compared to 23% in the same quarter last year
• Profit After Tax (PAT) before exceptional items surged by 59% to Rs. 87.00 crore

Operational Highlights

• Successful completion of a USFDA Good Clinical Practices (GCP) inspection of its Human Pharmacology Unit with no observations
• Received an Establishment Inspection Report (EIR) with a favorable Voluntary Action Indicated (VAI) outcome for the Biologics facility at Biocon Park
• Inaugurated a new, state-of-the-art, dedicated peptide laboratory
• Recognized by TIME magazine and Statista as one of the World's Most Sustainable Companies in 2025, ranking #1 in India among companies in the pharma and biotech sectors

Management Commentary

Peter Bains, Managing Director and CEO of Syngene International Limited, commented on the results, stating, "We are pleased with the growth performance in the first quarter, which is aligned with our expectations. Continued conversion of pilot programs into longer-term contracts within our Research Services business was the main driver underpinning this momentum."

Bains also highlighted progress in the Biologics manufacturing division, noting the start of operations at the Unit III facility in Bengaluru and advancing preparations for the Bayview facility in the U.S. later this year.

Deepak Jain, Chief Financial Officer, added, "Operating EBITDA margins came at around 24%, driven by both revenue growth and a focus on cost optimization. The current quarter's PAT includes a tax benefit arising from transfer of gratuity funds to Employee Gratuity Trust."

Annual Guidance Reaffirmed

Despite ongoing macroeconomic factors, Syngene's management remains confident in their outlook. The company reaffirmed that it remains on track to deliver results in line with its annual guidance. This positive stance comes as the company continues to strengthen and expand its scientific platform capabilities while maintaining awareness of current economic conditions.

As Syngene International continues to navigate the evolving landscape of contract research and manufacturing services, its strong first-quarter performance and strategic initiatives position it well for sustained growth in the coming quarters.

Syngene International Limited , a leading contract research organization, has reported a strong start to the fiscal year with an 11% year-on-year increase in revenue from operations for the first quarter ended June 30.

Financial Highlights

The company's consolidated revenue from operations rose to Rs. 875.00 crores in Q1, up from Rs. 790.00 crores in the same quarter last year. This growth was primarily driven by the continued conversion of pilot programs into longer-term contracts within the Research Services business.

*Excludes exceptional item of Rs. 21.00 crores (net of tax) in Q1 of the previous year relating to final settlement from an insurance claim.

Operational Highlights

• Syngene successfully completed a USFDA Good Clinical Practices (GCP) inspection with no observations.
• The company inaugurated a new state-of-the-art peptide laboratory, expanding its scientific platform capabilities.
• Operations commenced at the Unit III facility in Bengaluru, enhancing the Biologics manufacturing division.
• Preparations are underway to start operations at the Bayview facility in the U.S. later this year.

Management Commentary

Peter Bains, Managing Director and CEO of Syngene International Limited, commented on the results: "We are pleased with the growth performance in the first quarter, which is aligned with our expectations. Continued conversion of pilot programs into longer-term contracts within our Research Services business was the main driver underpinning this momentum."

Deepak Jain, Chief Financial Officer, added: "Operating EBITDA margins came at around 24%, driven by both revenue growth and a focus on cost optimization. The current quarter's PAT includes a tax benefit arising from transfer of gratuity funds to Employee Gratuity Trust."

Sustainability Recognition

Syngene was recognized by TIME magazine and Statista as one of the World's Most Sustainable Companies. The company ranked #1 in India among pharma and biotech companies and was placed in the top 20 life science companies globally.

Corporate Governance Update

The company has updated its list of Key Managerial Personnel authorized to determine materiality of events:

• Peter Bains as Managing Director and CEO
• Deepak Jain as CFO
• Chethan Yogesh as Company Secretary and Compliance Officer

Outlook

While remaining mindful of ongoing macroeconomic factors, Syngene maintains a confident outlook for the year. The company continues to invest in technology and capabilities to strengthen its customer offerings, supported by a robust balance sheet.

Syngene International Limited remains on course to deliver in line with its stated guidance for the year, focusing on growth, cost optimization, and expanding its global presence in the contract research and manufacturing services sector.